Open AccessThe Effect of a Losartan‐Based Treatment Regimen on Isolated Systolic Hypertension
Author(s) -
Cushman William C.,
Brady William E.,
Gazdick Lisa P.,
Zeldin Robert K.
Publication year - 2002
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2001.01481.x
Subject(s) - medicine , tolerability , losartan , placebo , blood pressure , regimen , cardiology , angiotensin ii , adverse effect , alternative medicine , pathology
This study was conducted to compare the antihypertensive efficacy and tolerability, over 12 weeks, of a losartan‐based treatment regimen and placebo in patients with isolated systolic hypertension. Three hundred eight patients ≥35 years of age with isolated systolic hypertension, defined as trough sitting blood pressure between 140 and 200 mm Hg systolic and between 70 and 89 mm Hg diastolic, were randomized to losartan 50 mg (n=157) or placebo (n=151) once daily, with titration as necessary to achieve a goal trough sitting systolic blood pressure (SBP) <140 mm Hg. At baseline, mean trough sitting SBP was 140–159 mm Hg in 20.5% of patients, 160–179 mm Hg in 62.7%, and 180–200 mm Hg in 16.9%, and was similar in the two groups (losartan, 165.3 mm Hg; placebo, 166.1 mm Hg). At 12 weeks, mean trough sitting SBP decreased significantly (p<0.001) in both the losartan‐based treatment group (by 19.2 mm Hg) and in the placebo group (by 7.6 mm Hg). The reduction in sitting SBP was significantly greater for losartan than placebo (−11.6 mm Hg; 95% confidence interval, −14.8 to −8.4). In patients with isolated systolic hypertension, a once‐daily losartan‐based treatment regimen significantly lowered SBP. The losartan‐based regimen exhibited antihypertensive efficacy that was superior to that of placebo, with a similar tolerability profile.